Aim To compare clinical baseline data in individuals with Type 2 diabetes and normoalbuminuria, who are at high or low risk of diabetic kidney disease based on the urinary proteomics classifier CKD273.
Introduction
Diabetic kidney disease (DKD) is a frequent and costly complication of diabetes. Despite established therapies, this complication is associated with substantial cardiovascular morbidity and mortality and is the leading cause of end-stage renal disease in the Western world [1] . In clinical practice DKD is diagnosed if albuminuria and/or a decrease in estimated GFR (eGFR) are present. Although treatment with renin-angiotensin system (RAS)-blocking agents in people with micro-and macroalbuminuria and control of cardiovascular risk factors have improved outcomes [2, 3] , the prognosis is still poor. Use of the aldosterone receptor antagonist spironolactone on top of RAS inhibition has previously been shown to further reduce albuminuria effectively [4] [5] [6] ; however, long-term as well as larger studies with hard endpoints such as end-stage renal disease are lacking.
Previous studies on RAS inhibition for the prevention of microalbuminuria have shown conflicting results [7] [8] [9] [10] . To our knowledge, no studies using spironolactone for the prevention of microalbuminuria have been conducted. Currently, there are no recommendations for the prevention of development of microalbuminuria in diabetes, except for optimal control of metabolic and cardiovascular risk factors.
Biomarkers based on pathways leading to the development and progression of DKD have the potential to identify people who are at high risk of progression to renal complications. This would allow early intervention only in the population at increased risk, leading to better allocation of treatment. In 2010, Good et al. [11] identified CKD273, a urinary biomarker pattern that includes 273 peptides significantly associated with overt kidney disease. This proteomics-based pattern detected initiation and progression of DKD earlier than the currently used indicators [12] [13] [14] [15] , far preceding change in albuminuria class; however, all previous data on CKD273 derive from analysis of stored samples and post hoc analyses of previously conducted studies.
In the ongoing PRIORITY study (Proteomic prediction and renin-angiotensin-aldosterone system inhibition prevention of early diabetic nephropathy in Type 2 diabetic participants with normoalbuminuria), we aimed, first, to test the hypothesis that the proteomic classifier CKD273 can predict development of microalbuminuria in people with Type 2 diabetes and normoalbuminuria prospectively, and second, to determine whether intervention with a mineralocorticoid receptor antagonist (spironolactone) on top of standard therapy can reduce the risk of developing microalbuminuria in individuals with a high-risk CKD273 score.
The primary objective of the present study was to evaluate clinical data in individuals stratified according to CKD273 risk pattern in this first prospectively recruited study population applying CKD273-based risk stratification. The secondary objectives were to evaluate associations between CKD273 and traditional risk factors for DKD and to compare participants in the high-and low-risk groups across centres to explore potential heterogeneity at study baseline.
Materials and methods

Study design
The ongoing PRIORITY trial is an investigator-initiated, prospective, randomized, double-blind, placebo-controlled international multicentre clinical trial and observational study in people with Type 2 diabetes and normoalbuminuria, funded by the European Commission's Seventh Framework programme. The detailed rationale, study design and methods for the PRIORITY study have been published elsewhere [16] .
Briefly, people aged 18-75 years with Type 2 diabetes, preserved kidney function and normoalbuminuria were included. The participants were required to fulfil the What's new?
• This paper describes baseline data from the first prospective multicentre study using the proteomics classifier CKD273 for risk stratification in individuals with normoalbuminuria and Type 2 diabetes.
• Previously, post hoc analyses have shown that CKD273 identifies individuals at high risk of developing diabetic kidney disease (DKD). The present study shows that the associations between the CKD273 proteomic pattern and traditional risk factors for DKD are weak, with small numerical differences for the traditional risk factors. CKD273 may provide additional information on risk of DKD.
• Interesting differences among sites across Europe in prevalence of CKD273 pattern cannot be explained by traditional risk factors for DKD.
following inclusion criteria: normoalbuminuria [urinary albumin:creatinine ratio (UACR) <30 mg/g] in at least two out of three consecutive morning void urine samples and eGFR >45 ml/min/1.73 m 2 at screening. Participants were stratified into high-or low-risk groups based on their CKD273 score, obtained from a single urine sample collected at screening. High risk was defined as a CKD273-classifier score >0.154 and low risk as a score ≤0.154, as previously described [15, 16] . Participants in the high-risk group were stratified based on use of RAS-blocking agents and randomly assigned to either spironolactone 25 mg once daily or placebo, on top of standard care. The participants in the low-risk group receive standard care. The study period has been extended from 3 to 4.5 years in a protocol amendment, primarily because of delayed recruitment. Based on expected higher progression rates to microalbuminuria because of an extension in treatment/observation time as well as new knowledge about treatment effect [10] , the estimated sample size was revisited with preserved statistical power. All participants are planned for a final visit in autumn 2018. The protocol and amendments have been approved by the respective national competent authorities partly based on the Voluntary Harmonization Procedure. Approval was obtained from the respective ethics committees for each participating clinical site. All participants provided written informed consent at screening, and again after the protocol amendment. The study is being conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. An external independent data monitoring committee will monitor safety throughout the study.
Biochemical and other analyses
At baseline, biochemical samples for measurement of creatinine, HbA 1c , potassium, sodium and lipids were analysed at the local routine laboratory at each study centre using standardized methods. eGFR was calculated at the local study centre and centrally using the Chronic Kidney Disease Epidemiology Collaboration equation, based on locally measured creatinine with a standardized method. UACR was measured at the central laboratory at the Steno Diabetes Centre Copenhagen using Vitros â 5600 MicroSlide. Samples were shipped frozen on dry-ice from study centres. Confirmed microalbuminuria was defined as UACR >30 mg/g in at least two of three first morning voids with a 30% increase (geometric mean) in UACR from the 'run-in phase', or >40 mg/g (geometric mean). Urine proteomics was performed by applying capillary electrophoresis mass spectrometry analysis at Mosaiques Diagnostics in Hannover, Germany. In brief, this provides data on >1000 identified proteins or peptides and a predefined renal risk profile based on 273 peptides (CKD273). The limit of detection for individual peptides is~1 fmol and mass resolution is >8000, enabling resolution of monoisotopic mass signals for z ≤ 6. The analysis has been described in detail previously [16, 17] .
Medical history
Data on concomitant medication, medical history, smoking status and diabetes duration were collected based on local medical records and self-reporting. Hypertension was defined as medical history of hypertension or concomitant treatment with antihypertensive agents at baseline. Dyslipidaemia was defined as dyslipidaemia noted in the medical history or concomitant treatment with lipid-lowering agents.
Statistical analysis
Continuous variables are reported as means (SD) for normally distributed data or median with interquartile range for skewed data and were compared between groups using an unpaired t-test; skewed data were log transformed before comparison between groups. A chi-squared test was used for comparison of categorical data. Correlations between baseline variables and CKD273 score were calculated from a linear regression model and are presented as coefficients of determination (R 2 ) and b-coefficients. Prediction of the highrisk group based on CKD273 was carried out using clinical variables in a logistic regression model, including known risk factors for DKD (age, gender, diabetes duration, systolic blood pressure, eGFR, logUACR, HbA 1c , smoking, retinopathy and use of RAS-blocking agents) and in individual models with logUACR, eGFR and use of RAS-blocking agents. A receiver-operating characteristic curve based on the logistic regression model including known risk factors for DKD is presented. Two-tailed P values <0.05 were taken to indicate statistical significance. SAS Enterprise Guide version 7.1 (7.100.1.2711, 64-bit) by SAS Institute, Inc., Cary, NC, USA was used for statistical analysis.
Results
Enrolment
From 25 March 2014 to the end of inclusion on 31 August 2016, a total of 2276 people from 15 study centres in 10 countries were screened and 1777 participants were included. Of those, 218 participants were in the high-risk group and 1559 participants were in the low-risk group. The proportion of participants in the high-risk group in the whole study population was 12.3%. The high-risk rates varied considerably between study centres, ranging from 0% to 27% (Fig. S1 ). The screening failure rate was 22% and varied between sites from 6% to 32%. The main reason for screening failure was presence of microalbuminuria with UACR >30 mg/g (n=133), followed by HbA 1c <48 mmol/mol (6.5%) or >119 mmol/mol (13%; n=71) and declining to participate (n=58) ª 2018 Diabetes UK as shown in the study flow diagram (Fig. S2) . Individuals who were not included in the study had a lower eGFR (P<0.01), a higher UACR (P<0.01) and higher potassium levels (P<0.01) compared with included individuals (Table S1 ). Screening failure was therefore most commonly attributable to previously unrecognized kidney disease at baseline.
Baseline characteristics and medication
In total, 1777 participants were included for proteomic assessment. Participants with a high-risk pattern differed from those with a low-risk pattern: high-risk participants were more likely to be men, were older, had longer diabetes duration, a lower eGFR and a higher UACR (P<0.02; Table 1 ). As mentioned, there was a wide range in the proportion of high-risk participants between sites, but there were no systematic differences in the traditional risk markers for DKD between centres (Table S2) . With regard to baseline medication, there were also differences between the highand low-risk groups (Table 2) . Biguanides were more commonly used in the high-risk group than in the low-risk (P<0.03), ACE inhibitors were used more frequently in the high-risk than in the low-risk group, whereas the use of AR 
blockers (ARB) was lower in the high-risk group (P<0.01).
Baseline concomitant medication, stratified by study site, is listed in Table S3 .
Medical history
In the entire study population, 13% had a history of background diabetic retinopathy, 3% of proliferative diabetic retinopathy and 4% of diabetic maculopathy. Laser treatment before baseline was performed in 4%. At baseline, 68% had a history of hypertension, 50% of dyslipidaemia and 12% of ischaemic heart disease. No difference was detectable in history of diabetic retinopathy or diabetic maculopathy between high-and low-risk groups (P>0.62), but more participants in the high-risk group had a history of hypertension, dyslipidaemia and ischaemic heart disease than in the low-risk group (P<0.02; Table 1 ). Medical history of participants according to study site is shown in Table S4 .
Correlation analysis with established risk factors
In the univariate regression analyses, CKD273 vs each baseline variable was found to have weak associations with age, diabetes duration, BMI, systolic blood pressure, eGFR, UACR, HDL cholesterol and triglycerides (P<0.04; Table S5 ). The strongest association was seen for UACR, with an R 2 value of 0.04 and a b-coefficient of 0.014 (P<0.01) and for eGFR, with an R 2 value of 0.03 and bcoefficient of -0.005 (P<0.01), suggesting that a maximum of 4% and 3% of the variation in CKD273 score could be explained by the variables eGFR and UACR, respectively. Scatterplots of CKD273 and UACR (Fig. S3 ) and of CKD273 and eGFR (Fig. S4) (Fig. 1) ]. In this model, gender, eGFR, logUACR and use of RAS-blocking agents remained significant determinants of the CKD273 high-risk group (P<0.01).
Discussion
In the present study, we describe baseline data from the PRIORITY study, prospectively applying the urinary proteomic-based CKD273 kidney disease risk classifier to a large population of individuals with normoalbuminuria and Type 2 diabetes. The ability of CKD273 to add prognostic information beyond the already available clinical data, including eGFR and albuminuria (within the normal range), has previously been demonstrated in post hoc analyses [13- (8) 106 (7) 24 (11) Other anti-platelet agents include warfarin, non-vitamin K-antagonistic oral anticoagulants and clopidogrel.
ª 2018 Diabetes UK 15, 18] ; however, the present ongoing study aims to further verify these findings and to assess the feasibility of this approach in the clinical setting. The aim of the present analysis was to evaluate if people with high and low risk of DKD, based on CKD273, in this setting would be easily differentiated using the standard clinical data, in order to assess the potential added value of the classifier.
The study included people with Type 2 diabetes and normoalbuminuria, from 15 sites in 10 European countries, on average with relatively long disease duration; in accordance with this, one-third of participants were being treated with insulin. Overall, the participants had reasonably well controlled HbA 1c , lipids and blood pressure, and normal kidney function with low albumin excretion and eGFR within the normal range. Small numerical differences were seen in baseline variables between the high-and low-risk groups. In particular, UACR, which is currently the best predictor of progression of DKD, was 5 (3-8) mg/g in the low-risk and 7 (4-12) mg/g in the high-risk group, being statistically, but not clinically, different. Weak correlations were seen between CKD273 and single baseline variables, with associations explaining <5% of the variability, suggesting that the proteomics score cannot be fully explained by established risk factors associated with DKD. When combining the known traditional risk factors for DKD in one model, an association with high-risk CKD273 score was seen.
Previous studies, all post hoc analyses of cohorts collected for other purposes without applying a standardized protocol for collection, storage, transportation or analysis of samples, showed that a high CKD273 score was associated with progression of renal disease in people without diabetes [18] [19] [20] . Other studies focused on CKD273 as a risk predictor specifically in a population with diabetes. Z€ urbig et al. [12] showed that CKD273 predicted progression from normo-to microalbuminuria 1.5 years before microalbuminuria occurred and that progressors from micro-to macroalbuminuria could be identified by the classifier 3-5 years before disease progression in adjusted models. At baseline there was a trend towards progressors being older and male, with a higher urine albumin excretion rate, a lower eGFR and higher systolic blood pressure compared with non-progressors. This is similar to the findings in the present PRIORITY study. The findings were confirmed by Roscioni et al. [21] in a small case-control study, in which they showed that CKD273, in addition to eGFR, predicted development of albuminuria stage over a 3-year period, also after adjusting for baseline urinary albumin excretion and eGFR [21] . In DIRECT-Protect 2, a study in participants with Type 2 diabetes, 9.8% were identified as having a high risk of DKD, a lower rate than in the present study; however, a higher CKD273 score threshold was applied [15] . The participants had similar urinary albumin excretion rate and blood pressure at baseline; however, they were younger, and had a shorter diabetes duration than the present population as well as a lower eGFR, which could partly explain the lower than expected high-risk rate observed in the PRIORITY study. Pontillo et al. [14] investigated a large population primarily diagnosed with diabetes (Types 1 and 2) with an eGFR decline of >5 ml/ min/1.73 m 2 per year as the primary endpoint. The authors reported that, for baseline ranges of eGFR >70 ml/min/1.73 m 2 , CKD273 had a superior predictive value to urinary albumin excretion for fast eGFR decline. These findings support the use of CKD273 in the present study population with relatively high eGFR. The average prevalence of the high-risk pattern was 12.3%, but ranged from 0 to 27% across centres. Although standardized procedures, including sampling protocols, are described for all centres, slight differences in sample handling and variances in diet and lifestyle between countries may occur, potentially influencing the urine proteome. The performance of CKD273 across centres was investigated by Siwy et al. [22] in a case-control study, where cases had macroalbuminuria and/or eGFR <45 ml/min/1.73 m 2 . The performance was similar across sites (area under the curve 0.89-1.00). The considerable variation in the high-risk CKD273 pattern rate between centres in the PRIORITY study might be explained by different recruitment strategies between centres, but when looking at the variation in baseline characteristics, there was no clear trend in the variables explaining the varying rates of high-risk individuals.
The study showed that it is feasible to have the results of the proteomics analysis within 3 days and therefore to use the test in a clinical setting. The capillary electrophoresis mass spectrometry analysis is a high-end technology and the cost is higher than testing for urinary albumin; however, if it is able to predict microalbuminuria, and progression to microalbuminuria can be prevented or delayed with selected preventive treatment, it may well be cost-effective [23] . Moreover, as the technology is developed further, the expectation is that the cost may be reduced.
We recognize that the present study has some limitations. Data on medical history and other baseline characteristics were partly self-reported, but were monitored in accordance with Good Clinical Practice. Even though the same inclusion and exclusion criteria were applied, it may have had an impact that some centres included participants from primary care, whereas others came from secondary care settings; however, the differences observed among the sites might reflect the nature of a multicentre setting and thus the study population will provide a more generalizable result. The risk stratification was based on proteomics analysis of one urine sample. We expect that the variation will be limited because of the large number of individual peptides included in the pattern [11] , but this issue has not been extensively studied. Microalbuminuria is an accepted clinically relevant surrogate for DKD, although it is not an approved hard endpoint; however, in studies for prevention, it is nearly impossible to analyse hard endpoints because follow-up of participants would last for decades.
The major strengths of the present study are the welldescribed phenotype of a large population with Type 2 diabetes and the prospective design, with 4.5 years planned follow-up.
In conclusion, in participants with Type 2 diabetes and normoalbuminuria, established risk factors for DKD differed only slightly, with numerically small differences between high-and low-risk participants, grouped according to the CKD273 score. Moreover, a limited correlation was seen between CKD273 and baseline variables, indicating that the proteomics score may not be explained by established risk factors and may thereby contribute additional information to the measures currently available in the clinic. Whether the classifier provides additional prognostic information to that of the clinical data will be evaluated in a follow-up of this cohort.
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